12
Jun
Industry spotlight – challenges and opportunities in the PMB sectors
Numbers show that the pharma, medical & biotech (PMB) sectors generated just under EUR 13bn worth of deals in H1 2024 in the Nordics, a more than fourfold increase from the same period the year before. This growth is a direct consequence of the strength in R&D and innovation, triggering interest from international buyers and investors in the sector and in the region. The panel will look at the potential for further growth within this and related industries that will contribute to the overall regional growth, as well as identifying which are the other sectors to watch in the year ahead.
Sectorial analysis: How are the pharma, medical and biotech sectors driving investment activity in the region, and which other sectors are particularly affected?
Impact of internationalisation on the sector: How are M&A deals boosting the marketing edge, penetrating new segments of the market, securing cutting-edge technologies and improve R&D?
Exit opportunities within the PMB sector: Which are the risks and the rewards?
A quick overview of the other emerging sectors: Technology, retail and consumer sectors, energy and infrastructure, mobility and digital – which sector will be top of the league in 12 months’ time?
-
SpeakersRachel Lewis Head of Auctions, EMEA Mergermarket
Sibel Arnes Healthcare & Life Science Director Adelis Equity Partners
Axel Schörling President EQL Pharma
Confirm cancellation
Something went wrong.
An error occurred trying to play the stream. Please reload the page and try again.
CloseSign-up to join the ION Analytics Community to:
- Register for events
- Access market insights
- Download reports
Sibel joined Adelis in 2022 where she focuses on Healthcare & Life Sciences investments. Sibel has been a board member at BBI Solutions (UK), Tempus Labs (US) and Mission Bio (US), and is currently on the board of SSI Diagnostica (DK) and IonOpticks (AUS). Prior to joining Adelis, Sibel worked as a Principal at Novo Holdings from 2016 to 2022 where she focused on life science and healthcare investments in Europe and the US. Sibel started her professional career at Bain & Company, where she worked primarily with private equity due diligences and corporate strategy for leading Nordic companies. Education: MSc, Finance & Strategic Management, Copenhagen Business School / CEIBS in Shanghai. BSc. International Business & Politics, Copenhagen Business School.